• Calliditas wins ‘Company of the Year’ at the European Mediscience Awards 2022

  • Calliditas is Proud to Support the IgA Nephropathy Community

  • Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape

Vision and Strategy

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Our Pipeline

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Share Price: Sweden

Share Price: US

Interim Report Q3 2022

On November 14, 2022, at 07:00 CEST, Calliditas Therapeutics published its interim report for the third quarter 2022.

Audio cast with teleconference: November 14, 2022, at 14:30 CET